NCT01360996View on ClinicalTrials.gov

Low Dose OC Therapy in Women With Polycystic Ovary Syndrome (PCOS): Impact of BMI on Hyperandrogenism

PHASE4CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions
Polycystic Ovary Syndrome
Interventions
DRUG

3 mg DRSP/20 μg EE

1 pill daily-24 days of drospirenone 3 mg (3 mg DRSP)/ethinyl estradiol 20 μg (20 μg EE)/levomefolate calcium 0.451 mg (folate) -followed by 4 days of levomefolate calcium 0.451 mg (folate)only

Trial Locations (1)

70815

Woman's Hospital, Baton Rouge

All Listed Sponsors
collaborator

Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma

INDUSTRY

lead

Woman's

OTHER

NCT01360996 - Low Dose OC Therapy in Women With Polycystic Ovary Syndrome (PCOS): Impact of BMI on Hyperandrogenism | Biotech Hunter | Biotech Hunter